Add rifampin for nosocomial MRSA pneumonia

In this trial of 93 patients with nosocomial MRSA pneumonia, they were randomized to IV vancomyin +/- rifampin. The combined therapy group had higher rates of 14 day clinical cure (54% vs 31%) but no difference in mortality. Adding rifampin to vancomycin may improve clinical cure rates in patients with MRSA pneumonia (abstract)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment